4 research outputs found

    Π­Ρ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ компрСссионной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ΅ Π²Π΅Π½ΠΎΠ·Π½Ρ‹Ρ… тромбоэмболичСских ослоТнСний Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с COVID-19

    Get PDF
    Background The main method for preventing thrombotic complications in patients with coronavirus infection is anticoagulant therapy (ACT). However, its use is not always possible, in particular in patients with bleeding. The only method of prevention in this case is elastic compression (EC) of the lower extremities.Aim of study To evaluate the effectiveness of lower extremity EC for the prevention of venous thromboembolic complications (VTEC) in patients with a new coronavirus infection.Material and methods The study was approved by the local Ethics Committee of the Ryazan State Medical University of the Ministry of Health of Russian Federation and registered on the ClinicalTrials.gov platform (identifier NCT05143567). The study included 69 patients without prophylactic compression (Group 1) and 65 patients who used prophylactic compression stockings (Group 2). The patients were treated in the covid hospital from July to November 2021. All patients had verified coronavirus infection, they took ACT and underwent ultrasound duplex scanning of the veins of the lower extremities upon admission, in the intensive care unit and upon discharge. We assessed the frequency of venous thromboembolic complications (VTEC), hemorrhagic complications, and mortality. To assess the severity of bleeding, the classification of the Committee of the International Society on Thrombosis and Haemostasis (ISTH) was used.Results In patients without prophylactic compression (Group 1) there were 7 VTEC cases (10.14%); deep vein thrombosis (DVT) β€” 4 (5.8%), pulmonary embolism (PE) β€” 3 (4.3%). All 6 cases (8.7%) with PE were fatal. It was noted that 2 cases of PE (2.8%) were verified upon autopsy, and not clinically. In patients of the 2nd group with the use of elastic compression, the overall incidence of VTEC was only one case (1.6%). When analyzing the frequency of bleeding in the 1st group, there was one pulmonary bleeding (1.4%), in the 2nd group there was also one case of intense intermuscular hematoma (1.6%). Significant bleeding was observed in one patient (1.4%) of the 1st group, and in 3 (4.8%) cases of the 2nd group. The minor bleeding was observed in 11 patients (15.9%) of the 1st group, and in 8 (12.7%) patients of the 2nd group. The mortality during hospitalization was 11 (15.9%) cases in patients of the 1st group (without EC) and 7 (11.1%) in patients of the 2nd group (with EC) (p=0.419).Conclusions The mortality in patients with coronavirus infection without compression therapy is higher than in patients with compression stockings (p=0.419). Patients wearing compression stockings in the hospital had a low incidence of VTEC (1.6% of cases in group 2 versus 10.14% of cases in group 1, p=0.039). The study groups had the same frequency of bleeding (group 1 β€” one case (1.4%), group 2 β€” one case (1.6%). The use of preventive compression at the inpatient stage of treatment of a new coronavirus infection makes it possible to prevent VTEC in patients with bleeding when anticoagulant therapy is not possible.ΠΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠžΡΠ½ΠΎΠ²Π½Ρ‹ΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ тромботичСских ослоТнСний Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ являСтся антикоагулянтная тСрапия (АКВ). Однако ΠΈ Π΅Π΅ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅ всСгда Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, Π² частности, Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с кровотСчСниями. ЕдинствСнным способом ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ Π² Π΄Π°Π½Π½ΠΎΠΌ случаС являСтся эластичСская компрСссия (ЭК) Π½ΠΈΠΆΠ½ΠΈΡ… конСчностСй.ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ ΠžΡ†Π΅Π½ΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ примСнСния ЭК Π½ΠΈΠΆΠ½ΠΈΡ… конСчностСй Π² ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ΅ Π²Π΅Π½ΠΎΠ·Π½Ρ‹Ρ… тромбоэмболичСских ослоТнСний (Π’Π’Π­Πž) Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π½ΠΎΠ²ΠΎΠΉ коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ ИсслСдованиС ΠΎΠ΄ΠΎΠ±Ρ€Π΅Π½ΠΎ Π»ΠΎΠΊΠ°Π»ΡŒΠ½Ρ‹ΠΌ этичСским ΠΊΠΎΠΌΠΈΡ‚Π΅Ρ‚ΠΎΠΌ Π€Π“Π‘ΠžΠ£ Π’Πž Π ΡΠ·Π“ΠœΠ£ ΠœΠΈΠ½Π·Π΄Ρ€Π°Π²Π° России ΠΈ зарСгистрировано Π½Π° ΠΏΠ»Π°Ρ‚Ρ„ΠΎΡ€ΠΌΠ΅ ClinicalTrials.gov (ΠΈΠ΄Π΅Π½Ρ‚ΠΈΡ„ΠΈΠΊΠ°Ρ‚ΠΎΡ€ NCT05143567). Π’ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ 69 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π±Π΅Π· примСнСния Ρ‚Ρ€ΠΈΠΊΠΎΡ‚Π°ΠΆΠ° (1-я Π³Ρ€ΡƒΠΏΠΏΠ°) ΠΈ 65 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ примСнялся профилактичСский компрСссионный Ρ‚Ρ€ΠΈΠΊΠΎΡ‚Π°ΠΆ (2-я Π³Ρ€ΡƒΠΏΠΏΠ°). Π‘ΠΎΠ»ΡŒΠ½Ρ‹Π΅ ΠΏΡ€ΠΎΡ…ΠΎΠ΄ΠΈΠ»ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π² ΠΊΠΎΠ²ΠΈΠ΄Π½ΠΎΠΌ госпиталС с июля ΠΏΠΎ Π½ΠΎΡΠ±Ρ€ΡŒ 2021 Π³. ВсС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π±Ρ‹Π»ΠΈ с Π²Π΅Ρ€ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ, ΠΈΠΌ Π½Π°Π·Π½Π°Ρ‡Π°Π»ΠΈ АКВ ΠΈ ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ΅ дуплСксноС сканированиС Π²Π΅Π½ Π½ΠΈΠΆΠ½ΠΈΡ… конСчностСй ΠΏΡ€ΠΈ поступлСнии, Π² ΠΎΡ‚Π΄Π΅Π»Π΅Π½ΠΈΠΈ Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ†ΠΈΠΈ ΠΈ ΠΏΡ€ΠΈ выпискС. ΠžΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ частоту Π²Π΅Π½ΠΎΠ·Π½Ρ‹Ρ… тромбоэмболичСских ослоТнСний (Π’Π’Π­Πž), гСморрагичСскиС ослоТнСния, Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ. Для ΠΎΡ†Π΅Π½ΠΊΠΈ тяТСсти ΠΊΡ€ΠΎΠ²ΠΎΡ‚Π΅Ρ‡Π΅Π½ΠΈΠΈ использовали ΠΊΠ»Π°ΡΡΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΡŽ ΠšΠΎΠΌΠΈΡ‚Π΅Ρ‚Π° ΠœΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠ³ΠΎ общСства ΠΏΠΎ Ρ‚Ρ€ΠΎΠΌΠ±ΠΎΠ·Ρƒ ΠΈ гСмостазу (International Society on Thrombosis and Haemostasis, ISTH).Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Π£ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π±Π΅Π· Ρ‚Ρ€ΠΈΠΊΠΎΡ‚Π°ΠΆΠ° (1-я Π³Ρ€ΡƒΠΏΠΏΠ°) Π’Π’Π­Πž составили 7 случаСв (10,14%); Ρ‚Ρ€ΠΎΠΌΠ±ΠΎΠ· Π³Π»ΡƒΠ±ΠΎΠΊΠΈΡ… Π²Π΅Π½ (Π’Π“Π’) β€” 4 (5,8%), тромбоэмболия Π»Π΅Π³ΠΎΡ‡Π½ΠΎΠΉ Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠΈ (ВЭЛА) β€” 3 (4,3%). ВсС 6 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (8,7%) с ВЭЛА β€” со ΡΠΌΠ΅Ρ€Ρ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ исходом. ΠžΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ, Ρ‡Ρ‚ΠΎ 2 случая ВЭЛА (2,8%) Π±Ρ‹Π»ΠΈ Π²Π΅Ρ€ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Π½Π° аутопсии, Π° Π½Π΅ клиничСски.Π£ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ с ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ эластичСской компрСссии общая частота Π’Π’Π­Πž составила всСго ΠΎΠ΄ΠΈΠ½ случай (1,6%). ΠŸΡ€ΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ частоты ΠΊΡ€ΠΎΠ²ΠΎΡ‚Π΅Ρ‡Π΅Π½ΠΈΠΉ Π² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ Π±Ρ‹Π»ΠΎ ΠΎΠ΄Π½ΠΎ Π»Π΅Π³ΠΎΡ‡Π½ΠΎΠ΅ ΠΊΡ€ΠΎΠ²ΠΎΡ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ (1,4%), Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ Ρ‚Π°ΠΊΠΆΠ΅ ΠΎΠ΄ΠΈΠ½ случай напряТСнной ΠΌΠ΅ΠΆΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎΠΉ Π³Π΅ΠΌΠ°Ρ‚ΠΎΠΌΡ‹ (1,6%). Π—Π½Π°Ρ‡ΠΈΠΌΡ‹Π΅ кровотСчСния Π² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ наблюдались Ρƒ ΠΎΠ΄Π½ΠΎΠ³ΠΎ больного (1,4%), Π° Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ β€” Ρƒ 3 (4,8%). ΠœΠ°Π»Ρ‹Π΅ кровотСчСния Π² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Ρ‹ Ρƒ 11 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (15,9%), Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ β€” Ρƒ 8 (12,7%). Π›Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Π²ΠΎ врСмя госпитализации Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ (Π±Π΅Π· ЭК) составила 11 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… (15,9%) , Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ (с ЭК) β€” 7 (11,1%) (Ρ€=0,419).Π’Ρ‹Π²ΠΎΠ΄Ρ‹ Π›Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ Π±Π΅Π· компрСссионной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π²Ρ‹ΡˆΠ΅, Ρ‡Π΅ΠΌ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ компрСссионного Ρ‚Ρ€ΠΈΠΊΠΎΡ‚Π°ΠΆΠ° (Ρ€=0,419). Π£ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Π½ΠΎΡΠΈΠ²ΡˆΠΈΡ… компрСссионныС Ρ‡ΡƒΠ»ΠΊΠΈ Π² стационарС, ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½Π° низкая частота развития Π’Π’Π­Πž (1,6% случаСв Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ ΠΏΡ€ΠΎΡ‚ΠΈΠ² 10,14% случаСв Π² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅, Ρ€=0,039). Π’ исслСдуСмых Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… Π±Ρ‹Π»Π° одинаковая частота Π±ΠΎΠ»ΡŒΡˆΠΈΡ… ΠΊΡ€ΠΎΠ²ΠΎΡ‚Π΅Ρ‡Π΅Π½ΠΈΠΉ (1-я Π³Ρ€ΡƒΠΏΠΏΠ° β€” ΠΎΠ΄ΠΈΠ½ случай (1,4%), 2-я Π³Ρ€ΡƒΠΏΠΏΠ° β€” ΠΎΠ΄ΠΈΠ½ (1,6%) случай). ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ профилактичСского Ρ‚Ρ€ΠΈΠΊΠΎΡ‚Π°ΠΆΠ° Π½Π° стационарном этапС лСчСния Π½ΠΎΠ²ΠΎΠΉ коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ позволяСт Π²Ρ‹ΠΏΠΎΠ»Π½ΡΡ‚ΡŒ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΡƒ Π’Π’Π­Πž Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с кровотСчСниями ΠΏΡ€ΠΈ нСвозмоТности провСдСния антикоагулянтной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ

    Coagulation Factor Activity and Hemostatic Markers of Endothelial Dysfunction in Patients with Peripheral Arterial Disease

    No full text
    Purpose: We aimed to evaluate the impact of intrinsic coagulation factors and hemostatic markers of endothelial dysfunction on complications in patients with atherosclerotic peripheral arterial disease (PAD). Materials and Methods : This prospective study enrolled 120 PAD patients at Fontaine stages 2b to 3 who underwent open surgical, endovascular, or conservative treatment. Coagulation factors (FVIII, FIX, and FXI) and endothelial hemostatic markers, including von Willebrand factor (vWF) activity and level, soluble endothelial protein C receptor, and plasminogen activator inhibitor-1 (PAI-1) levels, were assessed. Results : At 3 months after open bypass grafting, activity of FVIII significantly increased from a median of 175% to 233% (P<0.001). At 3 months after endovascular treatment, the activities of FVIII, FIX, and FXI significantly increased from medians of 157%, 180%, and 156% to 184%, 218%, and 181%, respectively (P<0.05). Six patients with increased FVIII activity developed bypass graft thrombosis. Four patients in the endovascular group and three patients in the conservative treatment group with increased activity of vWF developed myocardial infarction (P=0.049). The subjects who developed restenosis had increased vWF activity (P=0.023) and decreased nitric oxide metabolite levels (P=0.003). Three subjects who received conservative treatment and developed PAD progression at 12 months had increased PAI-1 activity (P=0.028). Conclusion : Patients with advanced PAD had a hypercoagulable status, and performance of open or endovascular revascularization was associated with further hypercoagulability. Increased activity of coagulation factors and altered levels of hemostatic markers of endothelial dysfunction were associated with PAD complications such as graft thrombosis, myocardial infarction, disease progression, and restenosis
    corecore